CO.DON AG: First Spherox transplantation successfully carried out in Switzerland

Berlin / Teltow / Leipzig, October 26.10.2020th, XNUMX - At the Inselspital Bern, one of the leading orthopedic centers in Switzerland, the first patient was treated with the autologous cartilage cell transplant Spherox. Last week Prof. Dr. medical dr phil. of course Frank M. Klenke, Deputy Clinic Director and Team Leader Knee and Sports Orthopedics at the University Clinic for Orthopedic Surgery and Traumatology at the Inselspital Bern, the drug.

Professor Klenke: "I am pleased that the first transplantation with Spherox in the Inselspital, the university hospital of the University of Bern, was successfully carried out with my team. The patient suffered cartilage damage as a result of sports trauma. I am confident that the patient will be able to pursue his professional and sporting interests once the rehabilitation is complete.”

Tilmann Bur, CEO of CO.DON AG: “In Switzerland, around 1.800 cases of cartilage damage are diagnosed every year, which basically fall within the indication of the drug offered by CO.DON. We would like to thank the Inselspital for the great commitment to offering these people a regenerative option so that after successful treatment they can master everyday life and sporting activities again without any symptoms.”

CO.DON AG develops, produces and sells endogenous cell therapies for the minimally invasive repair of cartilage defects. The drug offered is a cell therapy product for the minimally invasive treatment of cartilage damage in the knee joint using only the body's own cartilage cells. The method offered by CO.DON is currently used in over 200 clinics in Germany and has already been used in over 15.000 patients. CO.DON received EU-wide approval for this drug in July 2017, and approval for Switzerland in March 2019. At the Leipzig site, CO.DON built one of the largest plants for the production of human cells on an industrial scale for in-house and contract production. The shares of CO.DON AG are listed on the Frankfurt Stock Exchange (ISIN: DE000A1K0227). Board of Directors of the company: Tilmann Bur.

For more information, please visit www.codon.de.

Source: Press release from CO.DON AG dated November 26.10.2020th, XNUMX